ArticleMed-X2026
Scalable optical metasurfaces for ultrasensitive, label-free and real-time biosensing.
Article in Med-X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Novel biosensors based on optical metasurfaces offer superior sensing performance in compact form factors, with transformative potential spanning biomedical research, clinical diagnostics and drug screening. However, their translation to real-world applications is hindered by a strong reliance on sophisticated and expensive top-down nanolithographic techniques with limited accessibility and low throughput. Here, we demonstrate scalable, high-throughput metasurfaces with optofluidic integration for label-free biosensing, exemplified by high-quality large-area gold nanohole arrays via nanosphere self-assembly lithography. Through comprehensive resonance analysis, we identified a surface plasmon polariton-Bloch wave mode that is both highly sensitive and experimentally accessible using cost-effective setups with incoherent visible light. Moreover, to improve the mass transport and analyte capture, we optimized the functionalization scheme, microfluidic design, and the metasurface placement within the microfluidic channel. The versatile meta-sensors were demonstrated with a broad range of targets, from biomolecules such as immunoglobulin G, streptavidin, to streptavidin-coated nanoparticles, which mimic virus particles and extracellular vesicles. By holistically improving the nanopatterning quality, functionalization efficiency and optofluidic integration, we achieved an experimental refractometric sensitivity of 498 nm/refractive index unit at 736 nm wavelength, a limit of detection of 0.17 ng/mL for biomolecules and ≲1 × 10 Graphical Abstract: Supplementary Information: The online version contains supplementary material available at 10.1007/s44258-026-00090-w.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.